People · Operator
Named in public records as an officer, director or promoter · active 2010–2025 · Biotechnology, Pharmaceuticals, Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Civitas Therapeutics, Inc. | — | Biotechnology | Series C | $117.8M | $2.3B | 2010 |
| Ideaya Biosciences, Inc. | — | Biotechnology | Series C | $111.4M | $3.9B | 2016 |
| Normunity Holding Company, LLC | — | Biotechnology | Series C | $83.4M | $273.5M | 2022 |
| Triton Therapeutics, Inc. | — | Pharmaceuticals | Series B | $36.4M | $152.5M | 2025 |
| Siduma Therapeutics, Inc. | — | Biotechnology | Series B | $31.2M | $687.1M | 2021 |
| ALDEA Pharmaceuticals, Inc. | — | Biotechnology | Series A | $27.5M | $334.9M | 2011 |
| Land Medicine Inc. | — | Pharmaceuticals | Series B | $16.9M | $98.0M | 2024 |
| Cornovus Pharmaceuticals Inc. | — | Biotech / Pharma | Seed | $3.1M | $3.0M | 2016 |
| Helix Therapeutics, Inc. | — | Biotechnology | Seed | $2.8M | $111.0M | 2010 |
Timothy Shannon at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Timothy Shannon on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Rob Hopfner | 2 | 6 |
| John Walker | 1 | 17 |
| Wende Hutton | 1 | 16 |
| David Hirsch | 1 | 16 |
| Daniel Wagner | 1 | 13 |
| Kevin Rakin | 1 | 7 |
| Craig Crews | 1 | 6 |
| Sakae Asanuma | 1 | 6 |
| Paul Stone | 1 | 5 |
| Scott Phillips | 1 | 5 |
| Howard Rosen | 1 | 5 |
| Paul Fonteyne | 1 | 5 |
| Brian Daniels | 1 | 5 |
| Paulina Hill | 1 | 5 |
| Mark Iwicki | 1 | 4 |
| Andrea Franz | 1 | 4 |
| Sara Nayeem | 1 | 4 |
| Jeffrey Stein | 1 | 4 |
| John D. Diekman | 1 | 4 |
| Russell Tweeddale | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.